Product logins

Find logins to all Clarivate products below.


Impact of Improving Cancer Survival on Drug-Treatment Opportunities: The Case of CML and Prostate Cancer

Earlier diagnosis and advances in treatment have reduced cancer patients’ mortality over the past decade in the mature markets. Developing markets will continue to see benefits in cancer survival. Cancer patients’ risk of recurrence has also declined dramatically. These advances will cause the coming decade to see growth in the number of people living with cancer outpace growth in the number of cases diagnosed annually in many markets.

Related Market Assessment Reports

Report
Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…
Report
Prostate Cancer – Unmet Need – Unmet Need – Metastatic Hormone-Sensitive Prostate Cancer (US/EU)
Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…
Report
Prostate Cancer | Disease Landscape & Forecast | G7 | 2024
Hormonal agents are routinely used in all lines of therapy and thus dominate the treatment of prostate cancer. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant…
Report
Prostate Cancer – Geographic focus: China – China In-Depth – Prostate Cancer
The treatment of prostate cancer in China is undergoing a transformative phase, characterized by an increase in diagnosed incident cases due to improved screening techniques. This shift is…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in Breast Cancer, Ovarian Cancer, and Prostate Cancer (US)
Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…